Goldman Sachs Group Inc. restated their buy rating on shares of Shire PLC (LON:SHP) in a research report released on Wednesday morning. The brokerage currently has a GBX 6,300 ($77.97) price objective on the biopharmaceutical company’s stock.
A number of other equities analysts also recently commented on SHP. Royal Bank Of Canada reiterated an outperform rating on shares of Shire PLC in a research report on Wednesday, June 15th. JPMorgan Chase & Co. reiterated an overweight rating and set a GBX 6,300 ($77.97) price objective (up previously from GBX 5,600 ($69.31)) on shares of Shire PLC in a research report on Monday, August 1st. Jefferies Group lifted their price objective on Shire PLC from GBX 6,050 ($74.88) to GBX 6,600 ($81.68) and gave the stock a buy rating in a research report on Wednesday, August 3rd. Shore Capital reiterated a buy rating on shares of Shire PLC in a research report on Tuesday, June 14th. Finally, Deutsche Bank AG reiterated a buy rating and set a GBX 6,000 ($74.26) price objective on shares of Shire PLC in a research report on Monday, September 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have assigned a buy rating to the company’s stock. Shire PLC currently has a consensus rating of Buy and an average target price of GBX 5,841.33 ($72.29).
Shares of Shire PLC (LON:SHP) opened at 5087.00 on Wednesday. The stock’s 50 day moving average price is GBX 4,998.05 and its 200 day moving average price is GBX 4,592.96. The stock’s market capitalization is GBX 34.73 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.
The company also recently announced a dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 8th were issued a GBX 3.51 ($0.04) dividend. This represents a dividend yield of 0.07%. The ex-dividend date of this dividend was Thursday, September 8th.
In other news, insider Dominic Blakemore bought 133 shares of Shire PLC stock in a transaction dated Friday, September 30th. The stock was acquired at an average cost of GBX 5,010 ($62.00) per share, with a total value of £6,663.30 ($8,246.66).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.